We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $936M
1-Year Est. Return 195%
This Fund
S&P 500
This Quarter Est. Return
+13.95%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$1.96B
AUM Growth
-$393M
Cap. Flow
-$554M
Cap. Flow %
-28.28%
Top 10 Hldgs %
32.05%
Holding
103
New
18
Increased
14
Reduced
37
Closed
22

Top Buys

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$49.4M
2
HUM icon
Humana
HUM
+$46.2M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$26.7M
4
CNTA
Centessa Pharmaceuticals
CNTA
+$26.1M
5
ORKA
Oruka Therapeutics
ORKA
+$24.6M

Top Sells

Rank Stock Value
1
CI icon
Cigna
CI
+$61M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$53.9M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$50.4M
4
AVTR icon
Avantor
AVTR
+$45.4M
5
ISRG icon
Intuitive Surgical
ISRG
+$45.1M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CNTX icon
51
Context Therapeutics
CNTX
$54.3M
$14.5M 0.74%
7,417,155
-2,200
-0% -$4.88K
ZTS icon
52
Zoetis
ZTS
$32.5B
$13.9M 0.71%
+71,000
New +$13.1M
RCKT icon
53
Rocket Pharmaceuticals
RCKT
$343M
$13.8M 0.71%
749,000
-351,000
-32% -$7.19M
IMUX icon
54
Immunic
IMUX
$182M
$13.6M 0.7%
826,600
-63,697
-7% -$907K
BMY icon
55
Bristol-Myers Squibb
BMY
$130B
$13.6M 0.69%
+263,000
New +$12.3M
IMNM icon
56
Immunome
IMNM
$2.63B
$12.8M 0.65%
873,891
– –
RGNX icon
57
Regenxbio
RGNX
$615M
$11.9M 0.61%
1,132,564
-167,500
-13% -$2.04M
COGT icon
58
Cogent Biosciences
COGT
$6.95B
$10.8M 0.55%
1,001,000
+294
+0% +$2.86K
APGE icon
59
Apogee Therapeutics
APGE
$10.1B
$9.05M 0.46%
154,000
-333,000
-68% -$16M
PRVA icon
60
Privia Health
PRVA
$3.13B
$8.5M 0.43%
466,800
-297,400
-39% -$5.67M
HELP
61
Cybin Inc
HELP
$471M
$8.16M 0.42%
918,000
– –
ESTA icon
62
Establishment Labs
ESTA
$2.7B
$7.31M 0.37%
169,000
-362,000
-68% -$15.7M
CGEM icon
63
Cullinan Oncology
CGEM
$1.07B
$7.11M 0.36%
425,000
-1,134,826
-73% -$20.1M
IMCR icon
64
Immunocore
IMCR
$1.7B
$6.23M 0.32%
200,000
– –
DYN icon
65
Dyne Therapeutics
DYN
$4.28B
$5.93M 0.3%
+165,000
New +$6.57M
SNY icon
66
Sanofi
SNY
$109B
$5.76M 0.29%
100,000
-215,000
-68% -$11.6M
EDIT icon
67
Editas Medicine
EDIT
$402M
$5M 0.25%
1,465,000
+649,000
+80% +$2.83M
TMDX icon
68
Transmedics
TMDX
$2.64B
$4.33M 0.22%
+27,600
New +$4.25M
KZR
69
DELISTED
Kezar Life Sciences
KZR
$3.89M 0.2%
502,600
– –
QURE icon
70
uniQure
QURE
$2.52B
$3.32M 0.17%
+673,618
New +$4.39M
IMVT icon
71
Immunovant
IMVT
$7.99B
$2.82M 0.14%
99,000
-809,000
-89% -$23.9M
ANRO icon
72
Alto Neuroscience
ANRO
$1.07B
$2.75M 0.14%
+240,000
New +$2.94M
PRME icon
73
Prime Medicine
PRME
$558M
$2.69M 0.14%
694,000
– –
SYRS
74
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$2.29M 0.12%
1,063,000
-610,538
-36% -$2.19M
SCYX icon
75
SCYNEXIS
SCYX
$36M
$2.16M 0.11%
181,091
– –
1 2
3
4 5

Similar funds

NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
PWAM
Private Wealth Asset Management Cedar Rapids, Iowa $935M AUM 17.66% 1-Year Est. Return
LJAC
L.J. Altfest & Co New York $935M AUM 27.19% 1-Year Est. Return
NI
NetEase Inc Hangzhou, China $934M AUM 11.31% 1-Year Est. Return
MCM
Massar Capital Management Stamford, Connecticut $934M AUM 14.18% 1-Year Est. Return
TS
Tamar Securities Woodland Hills, California $934M AUM 26.74% 1-Year Est. Return
TW
TritonPoint Wealth Chevy Chase, Maryland $934M AUM 23.95% 1-Year Est. Return
PGA
Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return

Avidity Partners Management's Q3 2024 Portfolio in Review

As of Q3 2024, Avidity Partners Management held 103 positions worth $1.96B, down 17% from $2.35B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Avidity Partners Management withdrew a net $554M in Q3 2024, closing 22 positions and reducing 37 holdings. Its most notable exit was Cigna, an estimated $61M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Technology.

Against the trend, Avidity Partners Management opened a new position in UnitedHealth worth $51.1M.

  • Avidity Partners Management's largest Q3 2024 buy was UnitedHealth: 87,400 shares worth $51.1M.
  • Avidity Partners Management added most to Oruka Therapeutics in Q3 2024, an estimated $24.6M increase.
  • Avidity Partners Management's biggest Q3 2024 reduction was Avantor, cutting an estimated $45.4M.
  • Avidity Partners Management fully exited Cigna in Q3 2024, selling an estimated $61M.
  • Avidity Partners Management's ten largest holdings make up 32% of its $1.96B portfolio in Q3 2024.
  • Avidity Partners Management opened 18 new positions and closed 22 in Q3 2024.
  • Avidity Partners Management's portfolio value fell 17% quarter-over-quarter to $1.96B.

Based on Avidity Partners Management's 13F filing for Q3 2024, filed 14 Nov 2024.